These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29203787)

  • 1. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
    Walton JB; Farquharson M; Mason S; Port J; Kruspig B; Dowson S; Stevenson D; Murphy D; Matzuk M; Kim J; Coffelt S; Blyth K; McNeish IA
    Sci Rep; 2017 Dec; 7(1):16827. PubMed ID: 29203787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
    Walton J; Blagih J; Ennis D; Leung E; Dowson S; Farquharson M; Tookman LA; Orange C; Athineos D; Mason S; Stevenson D; Blyth K; Strathdee D; Balkwill FR; Vousden K; Lockley M; McNeish IA
    Cancer Res; 2016 Oct; 76(20):6118-6129. PubMed ID: 27530326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
    Zhang S; Iyer S; Ran H; Dolgalev I; Gu S; Wei W; Foster CJR; Loomis CA; Olvera N; Dao F; Levine DA; Weinberg RA; Neel BG
    Cancer Discov; 2021 Feb; 11(2):362-383. PubMed ID: 33158842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
    Saner FAM; Takahashi K; Budden T; Pandey A; Ariyaratne D; Zwimpfer TA; Meagher NS; Fereday S; Twomey L; Pishas KI; Hoang T; Bolithon A; Traficante N; ; Alsop K; Christie EL; Kang EY; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Alsop J; Beckmann MW; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; El-Bahrawy MA; Elishaev E; Erber R; Gayther SA; Gentry-Maharaj A; Gilks CB; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; Hernandez BY; Jakubowska A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Kluz T; Koziak JM; Kristjansdottir B; Le ND; Lener M; Lester J; Lubiński J; Mateoiu C; Orsulic S; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Soong TR; Steed H; Sukumvanich P; Talhouk A; Taylor SE; Vierkant RA; Wang C; Widschwendter M; Wilkens LR; Winham SJ; Anglesio MS; Berchuck A; Brenton JD; Campbell I; Cook LS; Doherty JA; Fasching PA; Fortner RT; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Menon U; Modugno F; Pharoah PDP; Schildkraut JM; Sundfeldt K; Swerdlow AJ; Goode EL; DeFazio A; Köbel M; Ramus SJ; Bowtell DDL; Garsed DW
    Clin Cancer Res; 2024 Aug; 30(16):3481-3498. PubMed ID: 38837893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
    Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of
    Teng K; Ford MJ; Harwalkar K; Li Y; Pacis AS; Farnell D; Yamanaka N; Wang YC; Badescu D; Ton Nu TN; Ragoussis J; Huntsman DG; Arseneau J; Yamanaka Y
    Cancer Res; 2021 Oct; 81(20):5147-5160. PubMed ID: 34301761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
    Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
    Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired
    Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
    Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
    Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
    Kim J; Coffey DM; Ma L; Matzuk MM
    Endocrinology; 2015 Jun; 156(6):1975-81. PubMed ID: 25815421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
    Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
    Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
    Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
    Köbel M; Yang RZ; Kang EY; Al-Shamma Z; Cook LS; Kinloch M; Carey MS; Hopkins L; Nelson GS; McManus KJ; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Fu Y; Reuss DE; Lee CH
    Gynecol Oncol; 2023 Nov; 178():80-88. PubMed ID: 37820398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
    McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
    Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.